Steris walked into this earnings season with a premium P/E tag and a reputation as a steady medical equipment compounder, yet the stock only moved about 2.5% higher to US$237.47 after the print. The market reaction looked calm compared with what the numbers actually signaled. Revenue reached US$1,492.7m and net income came in at US$200.1m for Q1 FY2027, while earnings per share hit US$2.05. The real story sits in how those profits stack up against Steris’s richer valuation and recent margin progress, which sets up the rest of this earnings breakdown.

Is STERIS really just 1.6% below fair value, or does the 28.8x P/E put the stock at a premium that the current growth outlook does not fully back up? Compare current pricing with the full valuation analysis for STERIS

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: US$1,492.7m vs. US$1,391.1m (up about 7.3%)
• Net Income, Q1 2027 vs. Q1 2026: US$200.1m vs. US$177.4m (up about 12.8%)
• Basic EPS, Q1 2027 vs. Q1 2026: US$2.05 vs. US$1.80 (up about 13.8%)
• Trailing Net Income, TTM Q1 2027 vs. TTM Q1 2026: US$805.0m vs. US$647.7m (up about 24.3%)

Prefer clean visuals instead of scanning through more Steris earnings tables and raw figures? See the company’s full financial picture with a focus on valuation in our interactive company report for STERIS.

Steris bull case leans on recurring strength

Bulls argue Steris can compound steadily as infection prevention spending shifts toward consumables and services tied to a growing installed base. Q1 results give that view some backing. Healthcare services rose 10% and consumables 9%, clearly ahead of capital equipment at 1%. That points to the mix shift supporters want to see. Group gross margin reached 46% and EBIT margin 23.8%, both higher year on year, which fits the claim that pricing and productivity can offset inflation and tariffs. Organic revenue grew 6% in constant currency, which lines up with the reaffirmed 6% to 7% full year organic growth outlook. The US$600m North Carolina chemistry project also fits the long term narrative of scaling high margin formulated chemistries. The trade off is higher near term capex and some restructuring charges, but the balance sheet at roughly 1.1x gross debt to EBITDA and US$800m free cash flow guidance supports that plan for now.

Bear case tests Steris margins and capital intensity

Bears focus on margin pressure, capital intensity and reliance on spending that could be sensitive to reimbursement and budgets. Q1 does not fully settle those concerns. Free cash flow of US$279.6m was lower than the prior year because working capital helped less, which shows cash generation is not on a straight line. Life Sciences margin slipped to 42.1% as productivity issues and inflation offset price and volume, and AST margins eased 60 bps with higher depreciation. Those segment moves align with the view that not all businesses can keep expanding margins at the same time. The US$600m North Carolina investment pushes capex to about US$450m this year with more elevated spend through FY2029, which increases execution and payback risk. Reaffirmed EPS guidance of US$11.10 to US$11.30 and ongoing buybacks show current profitability still covers that heavier investment phase.

After Steris lifted capex and accepted thinner cash conversion this quarter, review whether this execution risk is isolated. Scan our risk analysis for STERIS which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If the mix of higher margins, heavier capex and Steris trading at a richer P/E has your attention, register for free with Simply Wall St and add STERIS to a Watchlist to track price against fair value and wait for a setup that fits your plan. Once you own it or any other stock, use the Portfolio Command Center to cut through noise and focus on the most important updates to your holdings. For longer term conviction, tap into crowd views and thesis checks through the Community so you are not assessing STERIS in a vacuum. That way you can spot potential catalysts or risks earlier and stay ahead of the wider market.

Seeking Alternatives Beyond STERIS Today

Fresh stock ideas can move from under the radar to full breakout before most investors react. Do not get caught watching from the sidelines while momentum is flying. Act now.

• Spot resilient potential compounders with strong balance sheets before they get crowded by tracking our curated list of solid balance sheet and fundamentals stocks (49 results).
• Ride the tailwinds of next wave automation by scanning hand picked 36 robotics and automation stocks that could gain traction while industrial spending is still catching up.
• Zero in on electricity grid upgrades with 36 power grid technology and infrastructure stocks that might benefit as infrastructure projects move from planning stages to execution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.